GeoVax Secures Patent for Innovative Malaria Vaccine Design
June 25th, 2025 12:00 PM
By: Newsworthy Staff
GeoVax Labs, Inc. has been granted a U.S. patent for its novel vaccine construct aimed at preventing malaria, marking a significant step forward in the fight against the disease and enhancing the company's portfolio in infectious disease prevention.
GeoVax Labs, Inc. announced the issuance of U.S. Patent No. 12,329,808, covering a novel vaccine construct designed to prevent malaria infection. This patent supports the company's multi-antigenic VLP-MVA vaccine design, which is pivotal for developing products against endemic and emerging infectious diseases. The patented technology involves a recombinant Modified Vaccinia Ankara (MVA) viral vector that expresses immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria, aiming to enhance vaccine potency and induce comprehensive immune responses.
David Dodd, President and CEO of GeoVax, emphasized the importance of this patent in advancing vaccines for high-consequence pathogens and reinforcing the company's position in global health security. With over 135 granted or pending patent applications, GeoVax strengthens its strategic stance across oncology, infectious diseases, and biodefense platforms. Malaria, causing over 600,000 deaths annually, remains a critical health challenge, particularly in sub-Saharan Africa, highlighting the potential impact of GeoVax's innovative vaccine design.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
